Standard BioTools Inc. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments
Standard BioTools Inc. (LAB) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments of $557.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-25.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments · last filed 2021-02-25
- Standard BioTools Inc. adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for the quarter ending 2018-03-31 was $556.00K.
- Standard BioTools Inc. adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for fiscal 2018 was $557.00K.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 12 month |
|---|---|---|
| 2018-12-31 | $557.00K 10-K · filed 2021-02-25 | |
| 2018-03-31 | $556.00K 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |